42
https://pubmed.ncbi.nlm.nih.gov/38093344
This abstract suggests that middle size peptide drugs containing non-canonical amino acid residues require genotoxicity assessment similar to small molecule drugs, with modifications to the standard test battery such as including a mammalian cell gene mutation test and excluding (Q)SAR assessment on MSP-related impurities.
